ホーム>>AB-CHMINACA 2'-indazole isomer

AB-CHMINACA 2'-indazole isomer

カタログ番号GC41084

AB-CHMINACAは、中枢のCB1受容体の強力なアゴニストであるAB-FUBINACAに構造的に関連する合成カンナビノイド(CB)です。

Products are for research use only. Not for human use. We do not sell to patients.

AB-CHMINACA 2'-indazole isomer 化学構造

サイズ 価格 在庫数
1mg
$111.00
Please Inquire
5mg
$445.00
Please Inquire
50mg Please Inquire Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

AB-CHMINACA is a synthetic cannabinoid (CB) that is structurally related to AB-FUBINACA , a potent agonist of the central CB1 receptor. AB-CHMINACA 2'-indazole isomer is an isomer of AB-CHMINACA in which the cyclohexylmethyl moiety is attached at the 2 position of the indazole group, rather than at the 1 position. The physiological and toxicological properties of this compound are not known. This product is intended for forensic and research applications. This product is a qualified Reference Material (RM) that has been manufactured and tested to meet ISO17025 and Guide 34 guidelines. These materials are tested using validated analytical methods on qualified instrumentation to ensure traceability of measurements. All traceable RMs may be distinguished by their CofAs and can be downloaded below using the batch number located on the product label. For a representative CofA please contact our technical support.

レビュー

Review for AB-CHMINACA 2'-indazole isomer

Average Rating: 5 ★★★★★ (Based on Reviews and 8 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for AB-CHMINACA 2'-indazole isomer

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.